If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 10 of 61
A Phase 1b Study of Oral AS-1763 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non Hodgkin Lymphoma
Objective
A Phase 1b Study of Oral AS-1763 in Patients with CLL/SLL or NHL
Protocol No
CARNABIOSCIENCES-C1763102
Categories
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patie
Objective
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to
Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone andCarfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone andCarfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
Protocol No
BEIGENE-BGB-11417-105
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma
Objective
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell NHL
Protocol No
CARIBOU-CB10A-ANTLER-NHL
Categories
A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies
Objective
A phase 1 Study evaluating NX-5948, a BTK Degrader in Adults with Relapsed Refractory B-cell Malignancies
Protocol No
NURIX-NX-5948-301
Categories
Phase 1/1b, Open-Label, Dose-Escalation, Dose-Expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 (Azercabtagene Zapreleucel or "Azer-cel") in Subjects with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) a
Objective
Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL B-cell
Protocol No
PRECISION-PBCAR0191-01
Categories
An Open-label Phase I/II Trial of Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Systemic Light-Chain Amyloidosis
Objective
A Phase I/II Trial of Venetoclax + Dexamethasone in R/R Systemic Light-Chain Amyloidosis
Protocol No
COLUMBIAUNIVERSITY-AAAT8639
Categories
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)
Objective
Prospective, Observational Study of Participants at Risk for CGVHD
Protocol No
INCYTE-MA-GVHD-401-THRIVE
Categories
A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia
Objective
Phase 1-2 DISC-0974 in Myelofibrosis and Anemia
Protocol No
DISC-0974-102
Categories
A Phase 1b Open-Label Study to Evaluate the Safety and Anti-Cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-Cancer Agents in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Objective
Study of loncastuximab tesirine in R/R B-cell Non-Hodgkin lymphoma patients
Protocol No
ADCT-402-105-LOTIS-7
Categories
Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
Objective
A Screening Study to Assign People with Myeloid Cancer to a Treatment Study or Standard of Care Treatment within myeloMATCH
Protocol No
SWOG-MYELOMATCH
Categories